In the first five to seven years after menopause, women lose roughly 20 percent of their bone density — far more than at any other point in adult life. This rapid drop is why menopause and bone health are so closely linked: about half of women over 50 will eventually have an osteoporosis-related fracture, according to the Bone Health and Osteoporosis Foundation. Knowing what changes happen, when to screen, and what prevention works can meaningfully reduce that risk.
Why Menopause Affects Bone Density
Estrogen restrains the activity of osteoclasts — the cells that break down bone. When estradiol falls during the menopause transition, osteoclast activity increases relative to bone-building osteoblasts, and bone resorption outpaces formation. The result is rapid loss of trabecular bone in the spine, hips, and wrists.
According to the NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases, women may lose up to 10 percent of bone mass in the five years immediately following menopause, with continued slower loss thereafter. Approximately 20 percent of US women over age 50 have osteoporosis at the femoral neck or lumbar spine, and another 50 percent have osteopenia (low bone mass), per CDC data.
Risk Factors for Osteoporosis
Some risk factors are non-modifiable: female sex, advancing age, white or Asian ancestry, small frame, family history of osteoporosis or hip fracture, and early menopause (before age 45). Others are modifiable: smoking, excessive alcohol use (more than 2 drinks daily), low body weight, sedentary lifestyle, low calcium and vitamin D intake, and certain medications.
Medications associated with bone loss include long-term oral or injected glucocorticoids, aromatase inhibitors used for breast cancer, GnRH agonists, some anticonvulsants, and prolonged proton pump inhibitor use. Medical conditions including hyperthyroidism, hyperparathyroidism, celiac disease, inflammatory bowel disease, rheumatoid arthritis, and chronic kidney disease also raise risk. For broader context on midlife conditions, see our medical conditions guide.
Symptoms (or Lack of Them)
Osteoporosis is largely silent until a fracture occurs. The first clinical sign is often a fragility fracture — a bone breaking from a fall from standing height or less. Common sites are the wrist, spine, and hip. Vertebral compression fractures may cause back pain, height loss, and a forward stoop (kyphosis), but up to two-thirds occur without acute symptoms and are found incidentally on imaging.
Hip fractures carry serious consequences. According to CDC injury data, hip fractures in older adults are associated with significant disability, loss of independence, and increased mortality in the year following the fracture. This is why prevention before a first fracture is the goal.
How Bone Health Is Assessed
Dual-energy X-ray absorptiometry (DEXA or DXA) is the standard test for bone mineral density. Results are reported as T-scores comparing density to that of a healthy young adult. A T-score of -1.0 to -2.5 is osteopenia; -2.5 or below is osteoporosis. The USPSTF recommends DEXA screening for all women age 65 and older, and for postmenopausal women under 65 with elevated fracture risk based on tools like FRAX.
The FRAX tool, developed by the WHO, estimates 10-year fracture probability based on age, sex, BMI, and clinical risk factors. Many clinicians use FRAX to decide whether to initiate treatment for postmenopausal women with osteopenia. Vertebral imaging may be added when height loss exceeds 1.5 inches or when significant kyphosis develops. Lab tests may include calcium, 25-hydroxyvitamin D, TSH, complete metabolic panel, and sometimes 24-hour urine calcium and creatinine.
Prevention and Treatment
Foundational prevention starts with adequate calcium and vitamin D, weight-bearing and resistance exercise, smoking cessation, and moderating alcohol. The NIH Office of Dietary Supplements recommends 1,200 mg of calcium daily for women 51 and older, ideally from food sources first, and 600 to 800 IU of vitamin D, with higher doses if deficient. Resistance training two to three times per week and weight-bearing aerobic activity improve bone strength and reduce fall risk.
For women with osteoporosis or high fracture risk, several pharmacologic options exist. Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) are typically first-line and reduce vertebral fractures by roughly 40 to 70 percent. Denosumab (Prolia) is a twice-yearly injection alternative. Anabolic agents — teriparatide, abaloparatide, romosozumab — stimulate bone formation and are reserved for severe osteoporosis or those who fail other therapies.
Menopausal hormone therapy is FDA-approved for prevention of postmenopausal osteoporosis. The 2022 NAMS Hormone Therapy Position Statement supports its use for fracture prevention in women under 60 or within 10 years of menopause who are at significant risk and cannot use other agents. Selective estrogen receptor modulators like raloxifene reduce vertebral fractures and lower breast cancer risk but increase clot and hot flash risk. Perimenopausal women with severe vasomotor symptoms may gain bone benefit alongside symptom relief from hormone therapy.
When to See a Doctor
Women approaching or in menopause should discuss bone health at routine wellness visits, particularly when significant risk factors are present. Earlier DEXA scanning (before age 65) is appropriate for women with early menopause, low body weight, glucocorticoid use, secondary causes of bone loss, or strong family history of hip fracture.
Any fragility fracture — especially of the hip, vertebra, or wrist after age 50 — warrants formal osteoporosis evaluation regardless of prior screening status. Loss of height greater than 1.5 inches, new persistent back pain, or a noticeable change in posture should prompt vertebral imaging.
When to seek emergency care: Call 911 or go to the nearest emergency room after a fall with possible hip fracture (inability to bear weight, hip pain, leg shortened or rotated), sudden severe back pain after a fall or minor strain that may indicate vertebral fracture, or any head injury after a fall.
Frequently Asked Questions
How much calcium do postmenopausal women need?
The NIH recommends 1,200 mg of calcium daily for women 51 and older, ideally from food. Dairy, fortified plant milks, leafy greens, sardines, and tofu are good sources. Calcium supplements above 500 mg per dose are absorbed less efficiently and may be associated with kidney stones, so spreading intake is preferable when supplementing.
Does HRT prevent osteoporosis?
Yes. The Women’s Health Initiative found that estrogen therapy reduced hip fractures by about 33 percent. NAMS supports hormone therapy for fracture prevention in appropriate candidates, especially those with vasomotor symptoms who would benefit from treatment for both indications.
How often should I get a DEXA scan?
For most women with normal initial results, repeating in 5 to 10 years is reasonable. Those with osteopenia or risk factors typically rescan every 1 to 5 years depending on T-score and clinical context. Women on osteoporosis treatment usually rescan every 1 to 2 years to assess response.
Are bisphosphonates safe long term?
Bisphosphonates have been associated with rare side effects including atypical femur fractures and osteonecrosis of the jaw, mostly with prolonged use. Many guidelines suggest a “drug holiday” after 3 to 5 years for low-risk patients on stable therapy, with reassessment of fracture risk. Benefits in fracture prevention substantially outweigh risks for most women with osteoporosis.
Protecting Your Bones
The years right after menopause are the most critical for bone preservation, but bones remain responsive to lifestyle and medical therapy at any age. A combination of adequate calcium and vitamin D, regular resistance and weight-bearing exercise, fall prevention measures, and timely DEXA screening forms the foundation of prevention. For women with osteoporosis or high fracture risk, modern medications meaningfully reduce fractures. A clinician familiar with current osteoporosis guidelines can help match assessment and treatment to your individual risk profile.